Evaluation of Serum Lipids and C-peptide among Breast Cancer Patients with Chemotherapy

Basnyat, Anil Singh; Gyawali, Prabin; Jha, Anil Kumar; Risal, Prabodh; Shrestha, Bhupal Govinda

doi:10.3126/acclm.v2i2.15589

Cited by 1 publication

(1 citation statement)

References 16 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased level of serum LDH suggests the increase rate of enzyme leakage from mitochondria as a result of doxorubicin-induced toxicity [11]. A study by Basnyat et al [19] reported that elevated serum lipids level increased the risk of cardiovascular disease during BC management by FAC combination.…”

Section: Resultsmentioning

confidence: 99%

Study of Serum Lactate Dehydrogenase and Gamma-Glutamyl Transpeptidase in Breast Cancer Patients receiving Chemotherapy

Basnyat¹,

Jha²,

Pathak³

et al. 2017

JTLS

Self Cite

View full text Add to dashboard Cite

Breast cancer (BC) is the most common type of cancer worldwide, being one of the leading causes of morbidity in the female. In Nepal, it is the second most common type of cancer among women of perimenopausal age group. More than one-quarter of the BC is diagnosed in young Nepalese female, with a familial history of breast cancer, early pregnancy, longer lactation and estrogen exposure, often tumors showing aggressive biological behaviors. Anthracyclines (Doxorubicin) based treatment regime were reported to cause cardiotoxicity by increasing intramyocardial free radical production, lipid alterations and decreasing antioxidant level. Oxidative stress involving cellular reactive oxygen species (ROS) production is widely accepted mechanism, but the molecular basis of chemotherapyinduced organ toxicity remains highly controversial. An increased rate of metabolism and oxidative stress results in rapid turnover of cancer cells that modulates the enzyme level in blood circulation. Serum LDH and GGT level correlate with tumor burden, the metastatic character of BC and intensity of organtoxicity. The aim of our study is to evaluate the serum level of LDH and GGT in BC patients receiving chemotherapy and correlate these enzyme levels with different stages of BC. A total number of 150 subjects were included in the study, comprising 90 histopathologically confirmed 24 to 76 years aged patients of different breast cancer stages, receiving at least 3 cycles of 5-Fluorouracil, Adriamycin, and Cyclophosphamide (FAC) chemotherapy. Sixty age-matched healthy women were enrolled as controls. Blood samples from each were collected after informed consent and analyzed for serum LDH and GGT levels using standard biochemical methods. Data were analyzed using student's paired-T test, Pearson correlation test and ANOVA. Serum LDH and GGT levels were significantly (p < 0.001) increased in BC patients as compared to control group. When all 4 stages of BC were compared to control group, LDH and GGT activities showed a progressive increase from stage I to IV. The study concludes that serum LDH and GGT may be sensitive, specific and profitable biomarkers in early diagnosis of breast cancer, assessing cancer prognosis and response to treatment.

show abstract

Section: Resultsmentioning

confidence: 99%